From the publishers of JADPRO

Metastatic Triple-Negative Breast Cancer Resource Center

Advertisement

Apatinib Plus Etoposide as Second- or Higher-Line Treatment in Recurrent or Metastatic Triple-Negative Breast Cancer: A Single-Arm, Open Label, Prospective, Phase II Clinical Trial

Last Updated: Wednesday, July 6, 2022

The effect and safety profile of apatinib and etoposide have been demonstrated in several clinical trials for the treatment of late-stage TNBC. In this study, authors investigated the potential effect of combination therapy of apatinib plus etoposide, and found a promising clinical effect and acceptable toxicity in recurrent or metastatic TNBC.

2022 ASCO Annual Meeting
Advertisement
News & Literature Highlights
Advertisement
Advertisement